Metachromatic Leukodystrophy (MLD) Clinical Trial
Official title:
Gene Therapy for Metachromatic Leukodystrophy (MLD) Using a Self-inactivating Lentiviral Vector (TYF-ARSA)
This is a Phase I/II clinical trial of gene transfer for treating Metachromatic leukodystrophy (MLD) using a safety and efficiency improved self-inactivating lentiviral vector TYF-ARSA to functionally correct the genetic defect. The primary objectives are to evaluate the safety and efficacy of the gene transfer clinical protocol.
Metachromatic leukodystrophy (MLD) is a rare lysosomal storage disease. This disease is an inherited single gene autosomal recessive defect. MLD is caused by a mutation in the ARSA gene encoding arylsulfatase A which leads to a deficiency in sulfatide degradation, resulting in its accumulation in oligodendrocytes, Schwann cells and some neurons. A critical level of sulfatide storage can trigger demyelination, the hallmark of MLD, which results in multiple neurological symptoms. MLD has different onset ages including late infancy (1-2 years), adolescence (4 years-before sexual maturity) and adulthood (after sexual maturity). MLD patients are normally rescued by hematopoietic stem cell transplantation (HSCT) from a matched healthy donor. However, HSCT must be performed at a very early stage of the disease thus restricting its therapeutic opportunies in MLD patients. This trial aims to treat MLD using a safety and efficiency improved self-inactivating lentiviral vector carrying a functional MLD gene to correct the genetic defect by intracerebral injection to delivery the lentiviral vector carrying a normal ARSA gene to correct the pathogenic defect. The primary objectives are to evaluate the safety of the improved self-inactivating lentiviral vector TYF-ARSA, the in vivo gene transfer clinical protocol and the efficacy of degradative metabolite in patients at the time of treatment, assessment of vector integration sites, and finally the long-term correction of the related pathological symptoms. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05755568 -
A Study to Learn About Metachromatic Leukodystrophy (MLD) in Children in Spain
|
||
Terminated |
NCT01963650 -
Natural History Study of Children With Metachromatic Leukodystrophy
|
||
Active, not recruiting |
NCT01887938 -
An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leukodystrophy
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03771898 -
A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy
|
Phase 2 | |
Completed |
NCT00418561 -
Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)
|
Phase 1 | |
Completed |
NCT01510028 -
Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD)
|
Phase 1/Phase 2 | |
Completed |
NCT01043640 -
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
|
Phase 2 | |
Terminated |
NCT01372228 -
Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders
|
Phase 1/Phase 2 |